- Home
- RDW vs GLPG Comparison
RDW vs GLPG Comparison
Compare RDW & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDW
- GLPG
- Stock Information
- Founded
- RDW 2020
- GLPG 1999
- Country
- RDW United States
- GLPG Belgium
- Employees
- RDW N/A
- GLPG N/A
- Industry
- RDW Military/Government/Technical
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- RDW Industrials
- GLPG Health Care
- Exchange
- RDW Nasdaq
- GLPG Nasdaq
- Market Cap
- RDW 2.0B
- GLPG 2.1B
- IPO Year
- RDW N/A
- GLPG 2005
- Fundamental
- Price
- RDW $9.09
- GLPG $32.00
- Analyst Decision
- RDW Strong Buy
- GLPG Sell
- Analyst Count
- RDW 7
- GLPG 4
- Target Price
- RDW $17.50
- GLPG $25.33
- AVG Volume (30 Days)
- RDW 5.4M
- GLPG 407.4K
- Earning Date
- RDW 08-06-2025
- GLPG 07-23-2025
- Dividend Yield
- RDW N/A
- GLPG N/A
- EPS Growth
- RDW N/A
- GLPG N/A
- EPS
- RDW N/A
- GLPG N/A
- Revenue
- RDW $261,353,000.00
- GLPG $323,674,692.00
- Revenue This Year
- RDW $46.40
- GLPG N/A
- Revenue Next Year
- RDW $44.30
- GLPG N/A
- P/E Ratio
- RDW N/A
- GLPG N/A
- Revenue Growth
- RDW N/A
- GLPG 5.43
- 52 Week Low
- RDW $5.27
- GLPG $22.36
- 52 Week High
- RDW $26.66
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- RDW 29.32
- GLPG 53.21
- Support Level
- RDW $13.10
- GLPG $31.32
- Resistance Level
- RDW $9.77
- GLPG $32.63
- Average True Range (ATR)
- RDW 1.09
- GLPG 0.71
- MACD
- RDW -0.58
- GLPG -0.25
- Stochastic Oscillator
- RDW 5.60
- GLPG 29.13
About RDW Redwire Corporation
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.